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Abstract
Cells can use chemical modifications in chromatin to regulate accessibility to 
DNA to the repair complexes and to prevent transcription in case of damage. We 
analyzed the relationship between repair systems and epigenetic mechanisms in 
DNA and RNA. We searched the PubMed database for genes involved in DNA 
damage response (DDR) and methylation in mRNA and DNA repair, in cancer. 
Epigenetic modifications, particularly histone modifications and nucleosome 
remodeling, trigger a signaling cascade of kinases in DNA damage response (DDR) 
toward efficient repair. SWI/SNF remodelers promote the recruitment of repair 
factors in DNA, such as DNA double-strand breaks (DSBs) that activate kinases 
in DDR. RNA methylation via m6A has recently attracted attention as a possible 
alternative pathway for repairing DNA damage. m6A is a dynamic methylation 
mark on mRNA that accumulates after UV irradiation and regulates transcription to 
facilitate DNA repair. Currently, studies seek to understand how signaling pathways 
activate proteins in the early response to damage. The repair maintains DNA integ-
rity, which is a challenge in cancer because this process also represents a potential 
barrier to anticancer agents. The impact that epigenetic regulation can have on DNA 
repair is beginning to be understood.
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1. Introduction
Cells are exposed to a vast amount of exogenous genotoxic agents, such as 
ionizing radiation or UV light, or endogenous agents, including reactive oxygen 
species (ROS), derived from oxidative respiration or replication processes that 
can cause errors in the nucleotide chains. This damage interferes with different 
biological or metabolic processes, e.g., replication and transcription [1]. If these 
alterations are not properly repaired, then mutations, chromosomal aberrations, 
genomic instabilities, and other harmful effects can occur, triggering altera-
tions such as carcinogenesis. Cells developed complex systems to deal with these 
problems, as they have repair systems that are activated in response to checkpoints 
in the cell cycle to prevent cycle progression to eliminate damage or send cells into 
apoptosis, when repair is no longer possible. In cancer, the response to damage is 
mainly activated by genotoxic agents, double-strand breaking (DSBs) repaired by 
homologous recombination (HR) or non-homologous end joining repair (NHEJ). 
Cells have signaling networks to supervise the integrity and fidelity of the major 
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events of the cell cycle (checkpoints) until they recognize and respond to DNA 
structure damage and repair. This damage response cascade is known as DNA 
damage response and is responsible for control of genome stability after DSBs’ 
formation [2, 3].
Epigenetic modifications are alterations at the DNA level that do not cause 
permanent change in the sequence but might also cause conformational modifica-
tions. Here, chromatin plays an essential role, such that various damage response 
factors can gain access to the DNA sequence. Chromatin can be modified by 
histone changes, ATP-dependent nucleosome remodelers, and non-histone pro-
teins, including chaperones or a high mobility group (HMG). It demonstrates that 
reorganization of the dynamic chromatin structure is an intrinsic component of 
efficient DNA repair and DDR [4–6]. Epigenetic modification has gained relevance 
in recent years, which involves a change in RNA. In addition, 6-methyladenosine 
(m6A) methylation is one of the most common RNA modifications, and is visible 
in eukaryotic species, such as yeast to mammals and prokaryotes and bacteria and 
mycoplasma. There has recently been substantial progress in m6A epitranscrip-
tomics in its role in the initiation and progress of cancer. Studies on links between 
m6A and cancer yield different results in diverse tumors, suggesting that the effect 
of m6A modification can be variable: it affects proliferation, growth, invasion, and 
metastasis, but the involved pathways are just beginning to be unveiled [7, 8].
In this chapter, we will address chromatin modifications on DDR and how they 
function as therapeutic targets in cancer. Pathways that repair also create extraor-
dinary work in maintaining DNA integrity, but in cancer, they are a challenge, as 
they represent a potential barrier to anticancer agents.
2. Chromatin dynamic in the DNA damage response
The damage response triggers the rapid recruitment of repair proteins and 
checkpoint activation at the site of injury in DNA structure, a crucial step for DDR 
signaling pathway initiation. Cancer cells are characterized by deregulation in the 
signaling pathways that control checkpoint homeostasis, when genes associated with 
DDR suffer mutations, as the injury cannot be repaired correctly and is accumulated 
in the genome, triggering cellular transformation [9, 10]. Signaling pathways most 
affected will be those of apoptosis, cell cycle, and repair, contributing to harmful 
effects on genome integrity, thus increasing the risk of cancer [11]. Loss of function 
by germlines or somatic mutations of DDR-associated genes can trigger the inability 
of the repair single-strand break (SSBs) or DSBs, causing cell death [12]: this is the 
most deleterious type of DNA damage (since a single unrepaired DSB can be lethal).
The cell develops different repair mechanisms, such as base excision repair 
(BER), nucleotide excision repair (NER), mismatch repair (MMR), NHEJ and 
homologous recombination (HR) as well as homologous recombination repair 
(HRR) [2]. The specific type of DNA repair will be activated according to the 
lesion, the cell cycle phase, the genomic location, and the chromatin environment 
[3]. However, for this to occur, the processes associated with DNA repair pathways 
must overcome the physical chromatin condensation barrier and packaging to gain 
access, detect, and repair the damage. Cooperation with different histone modifica-
tions and nucleosome remodelers are involved in DNA repair [13]. The chromatin 
structure functions as part of the machinery regulating genome stability and 
provides necessary tools to carry out basic cellular processes for genetic information 
integrity.
Chromatin remodelers can alter or modify the chromatin structure, catalyzing 
the disruption of DNA-histone contacts and displacing or evicting nucleosomes 
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with ATP hydrolysis to gain access to DNA. They can then regulate the stiff-
ness, flexibility, and mobility of chromatin within the nucleus [14] or facilitate 
the accessibility of TFs to functional DNA elements, such as promoters or 
enhancers. Several ATP-dependent chromatin remodeling complexes have been 
directly implicated in DSB response. In yeast, INO80, SWR1, switch/sucrose 
non-fermenting (SWI/SNF), and remodeling the structure of chromatin (RSC) 
complexes are recruited to the DSB and reconfigure the nucleosomes around it 
so as to facilitate DNA repair and/or to modulate checkpoint activation. HMG 
B family is specifically involved in DSBs’ repair while promoting end joining in 
NHEJ in vitro [4, 5, 15, 16].
The SWI/SNF complex regulates the correct recruitment of repair factors for 
NHEJ and HRR and, signaling of DDR generated by DSBs [6]. In different cancers, 
up to 20% of the genes, mutated or altered, belong to the SWI/SNF complex 
[17]. Two subunits differ according to their composition, called Brahma-related 
gene 1 (BRG1)-associated factor (BAF) and BRG1 polybromo-associated factor 
(PBAF). Further, two ATPases BRM (SMARCA2) or BRG1 (SMARCA4) are mutu-
ally exclusive but structurally related [18, 19]. On the other hand, ARID1A/1B/2, 
PHF10, DPF1/2/3, PBRM1 (BAF180), beta-actin, SMARCE1 (BAF57), BCL7A/B/C, 
BCL11A/B, SS18, and BRD9, are subunits found in mammals, so it is probable that 
these proteins’ function are related to evolutive strategies in chromatin regulation 
associated with greater complexity and/or specificity to the SWI/SNF complex 
focalization [17]. In particular, the subunits SMARCA4, SMARCB1, ARID1A/B 
(BAF250A/B), PBRM1, and ARID2 have tumor suppressor function [20, 21]. 
this lack or silencing of a single protein, belonging to each subunit, can affect the 
interaction with other components of the SWI/SNF complex. The response to DNA 
damage was observed as nucleosome remodelers that interact through bromodo-
main with histone modifications and epigenetic marks (Figure 1).
Some functions for SWI/SNF subunits make it possible to understand the 
importance of this complex in cancer. Erket et al. [22] identified SMARCB1 as 
often lost or altered in malignant rhabdoid-type tumors. In addition, Agaimy et al.  
[23] and Nombiraan et al. [24] identified how alterations in SMACA4 compro-
mise patients with non-small cell lung cancer, which clarified the prognosis, 
diagnosis, and personalized therapeutic potential in patients with mutated or 
altered SMARCA4. In the study by Yoshida et al. [25], SMARCA4 loss of function 
is related to thoracic sarcomas. However, Herpel et al. [26] suggest that SMARCA4 
and SMARCA2 subunits, catalytic centers of SWI/SNF, should be added to diag-
nostic evaluation panels for lung adenocarcinomas, this is supported by results 
obtained in their work on protein expression by IHC, in more than 300 patients 
with non-small cell lung cancer. As earlier described, the proteins of the SWI/
SNF complex are involved in multiple mechanisms of DDR and DSB, while NER 
stands out, involved with other epigenetic modifications. This is demonstrated 
by Lee et al. [27], who observed that Brg1 subunit interacts with acetylated H3 in 
addition with H2AX in early stages of DNA damage, facilitating signaling, or DDR. 
Particularly in DNA repair, Ribeiro et al. [28] showed that both BRM and BRG1 
promote normal TFIIH (ERCC2) function in transcription and NER by regulating 
the expression of the GTF2H1 gene and found that cells with permanent BRM or 
BRG1 loss can restore GTF2H1 expression levels. Therefore, DNA damage sensitivity 
of BRM or BRG1 deficient cells correlates with GTF2H1 protein levels and can be 
used to select SWI/SNF-deficient cancers that are more sensitive to platinum drug 
chemotherapy. In studies carried out by Decristofaro et al. [29] and Watanabe et al. 
[30] in breast and lung cancer cell lines, respectively, they identified that expres-
sion of ARID1A or ARID1B was decreased or absent. They also found similar 
behavior in other SWI/SNF subunits (BRG1, BRM, BAF60a, BAF60c, BAF53a, and 
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SMARCB1). Duan et al. [31] identified that expression of ARID2 was significantly 
downregulated in hepatocellular carcinoma compared to adjacent nontumor 
tissue. Their research revealed that ARID2 inhibits cell cycle progression and 
tumor growth by interacting with the Rb-E2F signaling pathway. The relationship 
of E2F with epigenetic modifiers has become clear. Manickavinayaham et al. [32] 
demonstrated that the bromodomains of related acetyltransferases, p300 and CBP, 
specifically bind to the acetylated motif of E2F1; they found that interaction with 
acetylated E2F1 is critical for p300/CBP recruitment of DSBs and induction of 
histone acetylation at the sites of damage. They also demonstrated that in nucleo-
somes flanking DSBs, p300 and CBP mediate acetylation of multiple lysine residues 
on H3, including H3K18 and H3K56. Biswat et al. [33] and Guo et al. [34] demon-
strated that E2F2 induction of histone acetylation and chromatin decondensation 
in response to UV radiation promote efficient NER. Lin et al. [35] shows that ATR 
creates induction of E2F1 in DNA damage. ATM/ATR is known to activate P53 
in response to damage and plays a central role in DDR activation. ATM plays an 
important role in DDR and DSBs, as it regulates several pathways of cancer and 
epigenetic modifications.
Figure 1. 
The SWI/SNF complex in DNA damage response (DDR). (a) The biochemical characteristics of the BAF and 
PBAF subunits make the SWI/SNF complex a very heterogeneous family with exclusive properties in mammals. 
Alterations in this group of nucleosome remodelers give rise to cancer. (b) During DDR, SWI/SNF subunits 
interact through their bromodomains with histone modifications and epigenetic labels. For DNA repair to 
occur, it is necessary to activate the kinase cascades by ATM, responsible for recruiting and phosphorylating 
different repair genes such as E2F1, BRCA1 or 53BP1 and thus activating NER (nucleotide excision repair), 
HRR (homologous recombination repair)or NHEJ (non-homologous end joining), Ub: ubiquitination, Me: 
methylation, Ac: acetylation, P: phosphorylation, bromo: bromodomain.
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3. Chromatin modifications in DSB repair
DSB repair can activate two repair pathways in mammalian cells: the HRR and 
NHEJ. First it is active throughout the cell cycle, and second it is active in S and G2 
phases [36]. Usually, NHEJ is initiated by DSB recruitment of Ku70/80 or XRCC6 
XRCC5 heterodimer. Ku70/80 is DBS sensor and facilitates the downstream factors 
recruitment, including DNA-PKcs, PAXX, XLF, XRCC4, and ligase IV. Recruitment 
of downstream factors helps complete DNA repair. However, HRR involves MRE11-
RAD50-NBS1 (MRN) complex to activate ATM protein kinase [37]. Also, HRR can 
be influenced by PKcs and act in concert with the MRN complex and the recruit-
ment of this complex to DNA DSB by hSSB1 (single-stranded binding protein), as 
well as the activities of 53BP1/RIF1 and BRCA1/CtIP [38]. Cells start a cascade of 
phosphorylation events in response to DNA damage, mediated by three phospha-
tidylinositol-3-related kinases: ATM, ATR, and DNA-dependent protein kinase 
catalytic subunit (DNA-PKcs). The kinases activate a rapid reaction of abundant 
sensors for DSBs to check injuries, recruit effectors, and generate a coordinated 
response to maintain the genome integrity [37, 39].
Different epigenetic modifications are related to these kinases, while H2AX is an 
important chromatin-based substrate for phosphatidylinositol-3-related kinases, 
when it is phosphorylated on S139, and is named γ-H2AX. This phosphorylated 
form serves as a checkpoint for HR and NHEJ. The foci formation of γH2A.X is the 
most often observed epigenetic modification triggered by DNA damage; together 
with the response to DSB and the SWI/SNF complex, it promotes phosphorylation 
of S139 in its C-terminal region through ATM in human cells. Domains of γ-H2AX 
are established by contact with the DSB site. In fact, the break site defines the 
densities and spread of γ-H2AX [40–42]. In addition, PBAF functions in the ATM 
pathway silence transcription in cis on DSB by promoting mono-ubiquitination of 
H2A on K119 [43] and efficient early repair on exposure to ionizing radiation (IR), 
mediated by DSB and NHEJ [44]. H2AX induction by UV depends on ATR, but the 
formation of DSB in late stages contributes to ATM activation and the increase of 
H2AX. DNA-PKcs, after induction of DSB, is responsible for H2AX and chromatin 
remodeling factor (KAP1) phosphorylation. Furthermore, DNA-PKcs is required 
for chromatin remodeling in early postirradiation stages and promotes the rapid 
recruitment of DDR initiation proteins at DSBs sites [37]. An early modulator is 
BRIT, a chromatin-binding protein that forms irradiation-induced nuclear foci 
(IRIF) and works as a proximal factor at checkpoints in DNA, controls multiple 
damage sensors, and early mediators to DDR. BRIT1 colocalizes with γ-H2AX, 
using ATM/ATR to form the BRIT1-SWI/SNF interaction through its BAF170 and 
BAF155 subunits, potentiating the response to damage [45, 46].
Moreover, γ-H2AX recruits MDC in the chromatin, is phosphorylated by ATM, 
functioning as the protein coupling site of checkpoints and repair, such as 53BP1 
and the UBC13-RNF8-BRCA1 complex. The protein 53BP1 is phosphorylated by 
ATM and helps in the BRCA1 recruitment: together with the post-translational 
modifications in the damage site, they help promote other repair proteins. ATM and 
RNF8 facilitate the repair of DNA DSBs in the phases G1 and G2 of the cell cycle, 
regardless of the repair pathway used [47, 48]. Similarly, ubiquitination in the DSB 
regulates the repair protein BRCA1 and P53, as well as BARD1 recruitment by 53BP1 
[49]. BRCA1 and 53BP1 are necessary to regulate downstream histones phosphory-
lation and ubiquitination to direct the repair on NHEJ and HR. Thus, BRCA1 repairs 
DNA damage via HR, and 53BP1 plays a crucial role in the NHEJ repair pathway, 
ensuring DNA DSBs are repaired correctly [50, 51]. BRIT1 is required for DNA 
damage-induced intra-S and G2/M checkpoints, as regulation of the BRCA1 and 
Chk1 expression [52]. The loss of function of either of these two genes can alter 
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the HRR pathway, resulting in genetic instability and an increased risk of breast 
or ovarian cancer in BRCA1/2 germline mutation carriers [53, 54]. Cruz et al. [55] 
analyzed the RAD51 foci in 20 samples from patients with breast cancer, 10 in 
germinal-BRCA1, and 10 in germinal-BRCA2. The results provide new evidence of 
HRR restoration functionality as a frequent mechanism of PARPi resistance and 
demonstrate the potential of functional biomarkers to discriminate against tumors 
that will fail PARPi monotherapy. This emphasizes the major role played by ATM 
and DBSs-associated repair pathways in breast cancer treatment, whether mediated 
by IR or chemotherapy.
Qi et al. [56, 57] found that BRG1 decreases the nucleosomes stability at DSBs 
and creates an open and relaxed chromatin structure in SW13 and U2OS cells. It 
shows that BRG1 is crucial in early damage repair by remodeling the chromatin 
structure near DNA damage sites. They show that the BRG1 domain facilitates the 
RPA replacement with RAD51 at the DSB site in the HR, interacting with the RAD52 
mediator and regulating its recruitment into the DSBs. de Castro et al. [58] dem-
onstrated for the first time that Arid2 expression is important for HR. They found 
that Baf200 and Brg1 are required for efficient recruitment of Rad51 to a subset of 
DSBs, repaired by HR, where Rad51 and Arid2 are part of the same complex. Haokip 
et al. [59] demonstrated that SMARCAL1 and BRG1 regulate each other in HeLa 
cells with DNA damage-inducing agent doxorubicin, resulting in an increase in the 
SMARCAL1 transcription and protein. They found that BRG1 is present at the Enh1 
and Enh2 region of SMARCAL1 promoter in untreated HeLa cells. Experiments 
showed how BRG1 is present on SMARCAL1 promoter, with protein occupancy 
increasing when DNA is damaged, indicating that BRG1 can positively regulate 
SMARCAL1, creating a regulatory loop. Regarding the relationship with proteins 
of initial DDR pathway, Keka et al. [60] showed that the loss of Smarcal1 reduces 
the XRCC4 recruitment to DSB sites several times and suggests that Smarcal1 is 
required for DNA-PKcs/Ku70/Ku80 complex to the correct functions. Diplas et 
al. [61] found that loss of SMARCAL1 in glioblastoma cells can induce alternative 
lengthening of telomere (ALT) phenotypes, in the same way as ATRX. ATRX muta-
tions are the most prevalent abnormality in glioma, as Han et al. [62] identified that 
knockout ATRX inhibited glioma cell growth, tumor invasion, and a decrease in 
H3K9me3 availability, which can inhibit the ATM acetylation resulting in increased 
glioma cell chemosensitivity. They found that ATRX is involved in DNA damage 
repair by regulating the ATM pathway, suggesting a good prognostic marker in 
predicting temozolomide (TMZ) chemosensitivity.
Although little is known about the role of H1.2 in response to damage and 
interaction with the repair machinery proteins, its function has become clearer. Kim 
et al. [63] reported that p300-mediated acetylation of p53 and DNA-PK-mediated 
phosphorylation of H1.2 alter the p53-H1.2 interaction, thus alleviating the repres-
sive effects of H1.2 on the transactivation of p53. After DNA damage, p53 and H1.2 
undergo modifications in an orderly fashion, with H1.2 phosphorylation at T146 
followed by p53 acetylation. p53-H1.2 interaction is essential to enhance p53 func-
tion, and point mutations that mimic its constitutive modifications induce efficient 
growth inhibition and apoptosis. Li et al. [64] described a new mechanism to 
H1.2, without other H1 isoforms, to regulate the DNA damage response and repair 
through repression of ATM recruitment and activation. Moreover, H1.2 functions as 
a molecular brake for ATM binding to MRN, whereas DNA damage-induced ATM 
activation requires both the MRN complex assembly and H1.2 release. As such, 
these authors revealed a new link between chromatin disturbances, destabilization 
of H1.2, and ATM activation. For the first time, it was found that the RNF168/
RAD6 complex can promote mono-ubiquitination of histone H1.2 in vitro, and the 
H1.2 mono-ubiquitination can be induced after IR treatment. They concluded that 
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H1.2 mono-ubiquitination in vitro and in vivo by RNF168/RAD6 is evidence that 
mono-ubiquitination can establish a suitable microenvironment for other E2/E3 
complexes to catalyze polyubiquitination or multi-mono-ubiquitination of H2A 
and H2AX over H2A and H2AX ubiquitination, which is dependent on RNF8/Ubc13 
[65]. Thorslund et al. [66] proposed that linker H1 represents a key chromatin-
associated RNF8 substrate, whose UBC13-dependent K63-bound ubiquitylation 
at DSB-containing chromatin provides a scaffold to RNF168 binding through its 
UDM1 module. RNF168 ubiquitinates H2A into K13/K15 and possibly other pro-
teins to trigger repair factor recruitment in DSB. Giné et al. [67] implicated H1.2 as 
a valuable protein for apoptosis induction in chronic lymphocytic leukemia cells, 
and its release pattern is correlated with deletions of 17p and treatment response; 
they emphasized that histone H1.2 could be an essential apoptotic signal induced by 
agents acting independently of p53.
4. Methylation in DNA damage and repair
DNA methylation is considered a post-replication modification by the methyl 
group (–CH3) addition at carbon 5 cytosine, known as 5-methylcytosine (5mC), 
primarily in dinucleotides of CpG [68]. This enzymatic reaction is catalyzed by 
three DNA methyltransferases (DNMTs) (DNMT1, DNMT3A, and DNMT3B). 
These modifications are commonly found in promoter regions, the CpG islands, as 
their main function is transcription silencing, decreasing, or repressing the gene 
function. Methylation is the epigenetic modification most studied in cancer, as 
it is well-known that DNA hypermethylation can transcriptionally silence tumor 
suppressors and DNA repair genes, giving neoplastic cells survival advantages [69]. 
Various genes related to cell cycle regulation, tumor cell invasion, cell signaling, 
apoptosis, and chromatin remodeling are hypermethylated and silenced in almost 
all tumors. As demonstrated by Pal et al. [70] for the first time, CpG sites in the 
promoter of H2AX, RNF8, and CYCS are methylated; they show the collaborative 
participation of hypermethylation of DR5, DCR1, DCR2, CASP8, CYCS, BRCA1, 
BRCA2 and H2AX and the hypomethylation of DR4, FLIP, and RNF8 in sporadic 
breast cancer; the authors proposed that promoter methylation of these apoptotic 
and DDR genes is not due to a random phenomenon, as the progressive modifica-
tion of aberrant epigenetic alterations are associated with tumor advancement, 
which generates the dysregulation of the DDR-apoptotic pathway, promoting 
tumor development. Hinrichsen et al. [71] found that increased methylation in the 
promoters of MLH1, MSH2, PMS2, and p16 genes are correlated to an advanced 
stage in hepatocellular carcinoma. Epigenetic marks and DDR are crucial points to 
understand if changes in DNA methylation can contribute to resistance of cancer 
treatment, particularly by radiotherapy [72].
Various epigenetic marks have been associated with the response to damage, 
primarily the methylation of lysine 4 and 79 in H3 (H3K4me and H3K79me, respec-
tively) that contribute to DDR and DNA repair [73]. The marks on H3K4me1/2/3 
regulate the repair of DSBs through chromatin accessibility [74, 75]. Furthermore, 
H3K36 methylation is associated with “open” euchromatin and helps RNA pol II 
activate transcription [76]. Chang et al. [77] demonstrated that the tumor suppressor 
PHRF1 can move on the DSB due to H3K36me2/me3 and NBS1, then ubiquitinate 
PARP1, and trigger the subsequent repair by NHEJ. Yet, it is known that DOT1L 
methyltransferase catalyzes the H3K79 mono-di-trimethylation through its non-
SET domain. Recently, in the study by Kari et al. [78], the depletion or inhibition 
of DOT1L activity was shown to result in altered DNA damage response, indicated 
by decreased levels of γH2AX, but with increased KAP1 phosphorylation. Loss 
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of DOT1L function leads to faulty HRR-mediated DSB repair without affecting 
NHEJ. Highlighting DOT1L-mediated H3K79me3 importance in the early response 
to DNA damage and DSB repair, its inhibition also increases radiation sensitivity 
and chemotherapeutic agents in colorectal cancer patients’ treatment. Dot1L and 
H3K79 methylation was previously associated with the role of 53Bp1 in response 
to DNA damage [79]. FitzGerald et al. [80] corroborated that not only H3K79me 
recruits 53BP1 to DNA damage sites, but also H4K20me. This indicates that 
H4K20me concentration is essential for the repair pathway related to 53BP1 and 
BRCA1, in cooperation with the 53BP1-RIF1-MAD2L2 complex. The histone post-
translational modification of H3K27me3 and H4K20me is a diagnostic indicator in 
melanoma [81].
There is DNA methyltransferase, in which expression is regulated by epigenetic 
modification during DNA damage. MGMT is an O6-methylguanine-DNA methyl-
transferase responsible for the repair of damaged guanine, without other cofactors 
transferring the methyl at 06-meG to cysteine residues, removing adducts in a 
single step, thus protecting chromosomes from mutations, carcinogenesis, and 
alkylating agents [82, 83]. MGMT can do this only once, after its DNA-binding 
domain change by alkylating, which is detached from DNA and targeted for 
degradation by ubiquitination [84]. Loss of MGMT expression is due to promoter 
methylation [85], used as an advantage for good prognosis in a glioma, which can 
predict whether alkylating agents can benefit treatment [86]. MGMT can interfere 
with TMZ response on tumor cells and is responsible for efficient repair of TMZ 
and induced toxic DNA adducts, reducing treatment efficacy. Targeting MGMT 
seems to overcome chemoresistance in gliomas, but the prognostic value of MGMT 
methylation is controversial, as genomic rearrangements result in MGMT overex-
pression, independent of its promoter methylation, contributing to resistance [87].
5. Genome damage repair via m6A participation
Modified nucleotides on DNA create a vast list, shown by Fragou et al. [88], 
but methylation by methyltransferases is an epigenetic modification that occurs 
on DNA and RNA. In fact, RNA contains more modified bases than DNA, as these 
RNA modifications are present in rRNA, tRNA, snRNA, miRNA, or mRNA, giving 
rise to the emergence of a wide chemical diversity on its side chains. One of these 
modifications on mRNA has been studied since its discovery in 1974 [89, 90], the 
methylation of adenosine residues form N6-methyladenosine (m6A) is the most 
abundant post-transcriptional mRNA modification, and is detected in approxi-
mately 25% of mRNAs [91]. The m6A modification mechanism of action functions 
like methylation on DNA and histones, i.e., its presence or absence on mRNA 
determines the fate of the transcription. The addition of a methyl group to the N6 
site of A, occurring in the RRACH sequence [92, 93], has a distinctive position in 
the vicinity of stop codons, internal exons, in 5’UTRs which could promote 5’cap-
independent translation when found on the first nucleotide adjacent to the 7-meth-
ylguanosine cap; this gives protection from decapping [7, 94, 95] and in 3’UTRs 
regulates the affinity of RNA binding proteins [96]. This is known as m6A modifi-
cation, which is involved in a variety of cellular processes including gene expression 
through regulating RNA metabolism, such as mRNA translation, degradation, 
alternative splicing, export and folding [97, 98], control of protein translation [94], 
and others. All these effects are globally known as RNA epitranscriptomics.
For some time, m6A modification was considered static and unalterable, but is 
now well-known as reversible and dynamic. It is difficult to examine gene regulation 
at the RNA level without appropriate methods; genome-wide sequencing became a 
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major tool for many years, but had limitations with the m6A assay. The sensibility 
of the methodologies used was a critical point, because until recently, techniques 
had a detection limit of about 0.01%, in contrast to the content of m6A, less than 
0.001% is sufficient to regulate biological processes [99]. Antibody-based, high-
throughput sequencing technology allowed us for the past few years to locate the 
specific m6A sites and explore their biological significance. Linder et al. [91] solved 
the problem of distinguishing between m6A and adenosine by using incubation of 
an m6A-antibody to induce a specific mutational signature of m6A residues after UV 
light-induced antibody-RNA crosslinking and reverse transcription.
This modification is added and eliminated by proteins called “writers” and 
“erasers,” respectively; these proteins regulate the abundance, prevalence, and 
distribution of m6A; this exerts its biological function and is modulated by protein 
“readers.” First, m6A is added to the nucleus by the methyltransferase complex, 
which is formed by two core proteins, METTL3 and METTL4 [92]. METTL3/
METTL4 form a functional heterodimer, METTL3, which is the catalytic subunit 
which uses S-adenosylmethionine (SAM) or S-adenosylhomocysteine (SAH) as 
donors for methyl transfer in adenosine within the consensus motif G(G/A) ACU 
[100]. METTL4 has the active site blocked, and lacks amino acid residues to form 
hydrogen bonds with the ribose hydroxyls of SAM to facilitate donor and acceptor 
substrate binding; this is important in maintaining the integrity of the complex, 
stabilizing METTL3, and enabling RNA substrate recognition [101]. Regarding m6A 
demethylases or “eraser” proteins, FTO and ALKBH5 are two well-known m6A 
demethylases located in nuclear speckles within the methyltransferase complex. 
They belong to the group of Fe(II)/2-oxoglutarate (2OG)-dependent dioxygenases 
[102] and act on both DNA and RNA. FTO demethylates m6A through oxidative 
reactions that generate two intermediate hydroxymethyl6A and formyl m6A [103]. 
ALKBH5 catalyzes the direct removal of m6A, oxidizing the N-methyl group of 
the m6A site to a hydroxymethyl group, as its m6A demethylation function affects 
total RNA synthesis and mRNA export [104]. The “reader” proteins belong to the 
YTH domain family proteins, and in humans include YTHDF1–3 and YTHDC1–2. 
YTHDF1 stimulates mRNA translation to interact with eIFs and ribosomes. YTHDF2 
binds to m6A, located in the 3’UTR leading mRNA to become processing bodies 
for degradation in a methylation-dependent manner [105]. While YTHDC1 protein 
binds to m6A, as well as pre-mRNA splicing factor SRSF3 to its mRNA-binding 
elements, they are close to m6A sites but block SRSF10 mRNA binding, promoting 
exon exclusion, and modulating mRNA splicing by recruiting pre-mRNA splicing 
factors [106].
Damage to DNA is derived from replication stress, telomere shortening, UV 
light, chemical toxins, and ROS - but RNA can suffer alterations and respond to 
damage agents. This variety of DNA lesions is removed in cells by protein com-
plexes in specific repair systems (Figure 2). Until recently, response to damage was 
unique to DNA, while analyzing the response of DNA to UV, with Xiang et al. [107] 
changing that view. They found an accumulation of m6A on poly(A) + RNA two 
minutes after UV irradiation in response to DNA damage. They observed that the 
methyltransferase complex (METTL3, METTL4, WTAP) and Poly(ADP-ribose) 
polymerase (PARP) is localized to sites of UV-induced damage, with FTO demeth-
ylase recruiting. DNA polymerase translesion (Pol κ) is necessary for METTL3 and 
METTL4 recruitment. The authors suggested that PARP, METTL3, m6A RNA, and 
Pol κ could be alternative repair pathways to respond to UV-induced damage, with 
m6A in the main role for rapid recruitment of Pol κ to damaged sites. Colocalization 
of Pol κ with m6A to sites with a high content of cyclobutene pyrimidine dimers 
(CPDs) corroborate that m6A RNAs have a regulatory role in the NER pathway. 
Svobodová et al. [108] found that m6A RNAs are diffuse to damaged DNA, but 
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a new participant, METTL16, accumulated 20–30 min after induced damage in 
a subset of irradiated cells. This response was specific to CPDs, as the authors 
observed that m6A RNAs’ accumulation pattern was specific to repair of CPDs’ 
sites, which do not accumulate in other lesions, such as NHEJ.
Apyrimidinic or apuric (AP) sites can arise by spontaneous hydrolysis, cleaving 
the N-glycosidic bond through elimination of an incorrect or damaged base by 
DNA glycosylases or ionizing radiation. Considered one of the most predominant 
lesions in the genome, it is repaired by the BER pathway, which has PARP-1 as 
the first sensor and responder, activated by poly(ADP-ribose) polymerase [1]. 
Recently, Xiang et al. [107] found it was associated with m6A in RNA. AP lyases 
cleave 5′ or 3′ to AP sites to further processing by DNA polymerase and ligase. 
ALKBH1 is another member of the AlkB family that participates in demethylation 
of histone H2A in mouse stem cells. It is capable of cleavage to DNA at AP sites, 
using a lyase mechanism to produce a DNA nick on the 3′ side of a basic site, leaving 
a product that is missing a 3′-phosphate and an adduct in the 5’-DNA product. 
ALKBH1 acts on both ss-DNA and ds-DNA and can produce DSBs related to AP 
lyase activity. Human ALKBH1 possesses m6A demethylation activity, although 
this is not its main function. It cannot be ruled out this has a role in epigenetic gene 
silencing. Due to its abundance in mitochondria, it could play a primary role in 
mitochondrial DNA repair and function [109–111]. Other AlkB, such as ALKBH3, 
function as RNA repair enzyme; it is equally distributed in cytosol, the nucleus, 
and is active on RNA and ssDNA [112]. Zhang et al. [113] showed how METTL3 is 
phosphorylated by ATM protein for its localization to DSBs, where it catalyzes m6A 
in RNAs. METTL3 stimulates the recruitment of RAD51 to DSBs in a DNA-RNA 
Figure 2. 
Regulatory complexes of m6A in DNA damage repair. The m6A mark on mRNAs is involved in some repair 
pathways in response to DNA damage. It has been observed that the interaction of writing, eraser and reader 
proteins with other proteins that are part of canonical repair pathways is essential for the response to damage. 
SAM: S-adenosylmethionine; UV: ultraviolet light, NER: nucleotide excision repair, HRR: homologous 
recombination repair, eIFS: eukaryotic initiation factors, phosphate group: red circle.
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hybrid-dependent manner, promoting efficient homologous recombination-
mediated DSB repair. The upregulation of METTL3 may contribute to resistance to 
chemo- and radiotherapy.
6. Cancer drugs: resistance and epigenetics
Alterations in m6A and proteins responsible for its regulation on the RNA level 
were shown to interfere with the response to cancer treatment. Cyclophosphamide 
(CTX) is an alkylating chemotherapy drug used in cancer treatment; it forms 
adducts at the N7-guanine position, which are unstable and therefore undergo 
spontaneous dissociation. These features are exploited in rapidly dividing cells, 
which are likely to be disrupted before repair takes place [114]. Little is known 
about CTX effect on RNA epigenetic complexes, yet it was shown to increase m6A 
levels, inhibiting the gene and protein expression of FTO, YTHDF1, YTHDF2, 
YTHDC1, and YTHDF3 in a time- and concentration-dependent manner [115].
Cervical squamous cell carcinoma (CSCC) is an example of increased che-
motherapy resistance; Zhou and colleagues [116] found that β-catenin is an FTO 
target: they observed FTO overexpression and reduced m6A β-catenin levels, with 
the effect of this change upregulation of β-catenin protein and the subsequent 
activation of ERCC1, a critical player in NER, which contributes to chemotherapy 
resistance and a poor prognosis. In case of BRCA-mutated epithelial ovarian cancers 
(EOC), the use of Olaparib has been clinically beneficial: it is a poly(ADP-ribose) 
polymerase inhibitor (PARPi), which detects and binds DNA SSBs and DSBs, 
using the N-terminal DNA binding domain [117, 118]. When DNA is damaged, 
PARP-1 can recognize damaged sites and their formation; the binding exposes 
the enzymatic site of PARP-1, resulting in its activation and the recruitment of 
XRCC1, the first protein for assembly and activation of DNA bases excision repair 
machinery [119]. The resistance of tumor cells to PARPi is not well-known, but in 
the study of Fukumoto and colleagues [120], FZD10 was observed as a receptor in 
Wnt/β-catenin signaling, increasing m6A modification of mRNA in resistant cells, 
thus stabilizing. This increase contributes to PARPi resistance by upregulating the 
Wnt/β-catenin pathway in BRCA-deficient EOC cells.
Xiang et al. [107] showed that FTO could be recruited to damaged γH2AX 
chromatin after irradiation, strengthening FTO participation in DNA damage 
repair. In melanoma, FTO is upregulated and promotes cell proliferation, cell 
migration, invasion, and cell viability. Yang et al. [121] demonstrated that FTO 
regulates PD-1 expression that also promotes mTOR signaling. FTO can promote 
resistance to anti PD-1 blockade in melanoma through m6A, mediating PD-1 
(PD-1 or PDCD1 is a negative regulator of T-cell activity). This supports the anti 
PD-1 blockade with an anti-tumor response in advanced cancers and reduces 
immune-related adverse side effects, vs. with ipilimumab.
Glioblastoma is a common and aggressive primary brain tumor in adults, and is 
highly resistant to treatment such as surgery, irradiation, and adjuvant TMZ chemo-
therapy, which failed to improve the outcome. One cause of poor response to TMZ, 
as suggested by Visvanathan et al. [8], is that GSCs show high levels of m6A and 
METTL3, supporting the proposal that METTL3 is key in GSC maintenance, making 
those cells resistant to therapy and refractory to radiotherapy by efficient repair 
of DNA. Here, METTL3 alters the DNA repair efficiency and radiation sensitivity 
through m6A sites in SOX2–3’UTR, stabilizing it in GSC, as the recruitment of 
human antigen R (HuR) to m6A modified mRNA is crucial for SOX2 stabilization 
by METTL3. This supports a role for METTL3, shared with SOX2 in another repair 
pathway, mediated HR: SOX2 protects GSCs from radiation-induced cytotoxicity 
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by promoting HR repair, implying an oncogenic role for METTL3 and m6A. At the 
same time, FTO becomes a promising target to develop FTO inhibitors like Rhein, 
Meclofenamic acid (MA2), or its ethyl ester form, MA2 [122].
Hepatocarcinogenesis is correlated with abnormal m6A modifications, high 
METTL3 and YTHDF1 expression in hepatocellular carcinoma (HCC) is associated 
with poor prognosis, with its combination as a malignant marker, according to Zhou 
et al. [123]. The participation of the machinery regulating m6A was clarified by the 
work of Chen et al. [124]. They found a significant increase in mRNA m6A levels, 
supporting the role of m6A in liver cancers. When METTL3 is downregulated, it is 
unable to act on tumor suppressor SOCS2, being silenced by METTL3 through m6A-
YTHDF2. SOCS2 transcripts are a direct target of YTHDF2 with mediated mRNA 
decay, promoting tumor progression. Recently, Lin et al. [125] found that METTL3 
depletion leads to a resistant phenotype in HCC with sorafenib treatment through 
regulation of FOXO3 expression. FOXO3 m6A methylation maintains stability, but 
its absence accelerates degradation. The modification is read by YTHDF1, which 
stabilizes m6A-labeled RNA and promotes protein synthesis. These results con-
trast with those obtained by Taketo and colleagues [126] when they established a 
METTL3-KD using a pancreatic adenocarcinoma cell line. The authors concluded 
that these cells had higher sensitivity to gemcitabine, 5-fluorouracil, cisplatin, and 
irradiation. It is clear that METTL3 plays a key role in resistance to therapy, but the 
way this gene behaves in different types of cancer is not yet understood. In a study 
on colorectal cancer (CRC), it was found that c-Myc activates the YTHDF1 gene 
expression. YTHDF1 is overexpressed in CRC and has been associated with lymph 
node metastasis and poor prognosis, as the evidence in vitro with YTHDF1 knock-
down indicates that cancer cells are sensitized to the exposure of 5-Fluorouracil and 
L-OHP (oxaliplatin) [127].
7. Conclusions
The SWI/SNF complex has been shown to be a central regulator in DNA repair, 
over other epigenetic complexes such as Polycomb repressive complex 1 (PRC1) 
and 2 (PRC2), which require the cooperation of their subunits and epigenetic 
markers to trigger the on–off signaling cascade, generated by acetylation, methyla-
tion, or ubiquitination of genes involved in response to DNA damage. We see that 
participation of epigenetics in the cellular responses goes far beyond DNA pro-
moter methylation and histone modification. Methylation of RNA has a critical role 
in cell maintenance, changing our notion about RNA functions. We do not know 
whether deregulation of the m6A machinery could result in cancer development 
or progression by altering DNA damage response, but knowledge of molecular 
mechanisms of regulation of m6A cellular modification in tumor cells may develop 
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